AYA.AX Artrya Limited ASX after hours A$4.15: AI-driven Salix lifts outlook
AYA.AX stock traded after hours at A$4.15 on 26 Jan 2026, holding near the day high after recent momentum. Investors are watching Artrya Limited (ASX) for signs that its AI-powered Salix platform can convert pilot wins into recurring revenue. Key metrics show market cap A$478,210,400.00, EPS -0.18 and a 50-day average price of A$3.93. This note links product traction to valuation and short-term technicals, and highlights the upcoming earnings date on 24 Feb 2026 as a potential catalyst.
AYA.AX stock: price and trading snapshot
Artrya Limited (AYA.AX) closed at A$4.15 after hours, with intraday range A$3.87–A$4.15 and volume 342,272. The stock sits above its 50-day average of A$3.93 and well above the 200-day average of A$2.18, signalling recent buyer interest. Market cap stands at A$478,210,400.00 on the ASX in Australia.
Revenue, margins and valuation for AYA.AX stock
Artrya reports EPS -0.18 and a trailing PE of -23.44, reflecting negative earnings. Price-to-book is 20.43, and price-to-sales is elevated at 17,078.94, driven by low reported revenue. Current ratio is 8.27, and cash per share is A$0.11, which gives the company funding runway but underscores early-stage revenue conversion risk.
Product and commercial outlook: Salix and AI opportunity
Artrya’s Salix automates coronary artery disease detection from CT angiography. Commercial wins and regulatory progress shape AYA.AX stock momentum. Management cites pilot contracts and cloud deployments that could push recurring ARR if conversion accelerates. Watch contract expansion and reimbursement pathways as key revenue triggers.
Technicals and market sentiment for AYA.AX stock
Momentum indicators show an overbought setup: RSI 70.89 and MFI 82.92. MACD is positive with MACD 0.40 and signal 0.32. ADX at 40.86 signals a strong trend. Average daily volume is 846,381, and today’s volume was lower at 342,272, so monitor flows for follow-through or pullback.
Meyka Stock Grade and analyst context
Meyka AI rates AYA.AX with a score out of 100: 59.16 | Grade C+ | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. Independent analyst signals on Investing.com show mixed technicals and one analyst buy consensus Investing.com consensus.
Risks, catalysts and how to watch AYA.AX stock
Primary risks are revenue conversion, high valuation multiples, and continued negative margins. Catalysts include the earnings announcement on 24 Feb 2026, regulatory approvals, and signed recurring contracts. For sector context, healthcare IT on the ASX shows modest YTD performance versus cyclicals, so monitor sector flows and hospital procurement cycles.
Final Thoughts
Key takeaways on AYA.AX stock: Artrya trades at A$4.15 after hours with significant upside priced into growth. The company shows strong liquidity with current ratio 8.27, but it runs at negative margins and EPS -0.18, which keeps valuation stretched. Meyka AI’s forecast model projects yearly A$7.30, implying an upside of 75.98% versus the current price of A$4.15. Shorter-term models show a quarterly target of A$6.10 (+47.00%) and a monthly level near A$4.06 (-2.17%). These forecasts are model-based projections and not guarantees. Watch the 24 Feb 2026 earnings release, sales contract updates, and technical flows for trading and investment signals. For deeper metrics and live AI-powered market analysis visit our Artrya page on Meyka AI Artrya on Meyka and check technical notes on Investing.com technical analysis.
FAQs
What is the current price of AYA.AX stock?
AYA.AX stock trades at A$4.15 after hours on 26 Jan 2026. The intraday range was A$3.87–A$4.15 with volume 342,272. Watch the next earnings date on 24 Feb 2026 for updates.
What are the main risks for AYA.AX stock investors?
Main risks include continued negative earnings (EPS -0.18), very high valuation multiples, slow revenue conversion, and dependency on clinical adoption. Regulatory and reimbursement delays could also pressure AYA.AX stock performance.
What catalysts could move AYA.AX stock higher?
Catalysts are stronger recurring revenue from Salix, regulatory approvals, published clinical outcomes, and positive results at the 24 Feb 2026 earnings announcement. Contract renewals with hospitals would be a clear positive for AYA.AX stock.
What is Meyka AI’s view and forecast for AYA.AX stock?
Meyka AI’s forecast model projects yearly A$7.30, a 75.98% implied upside from A$4.15. Meyka AI rates the stock C+ (59.16) with a HOLD suggestion. Forecasts are model-based projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
